Rupesh Pophale

Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials

Florian Lordick, Eric Van Cutsem, K. Shitara et al. · ESMO Open · 2024 · 18 citations · Full text

Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.

Kohei Shitara, Rupesh Pophale, Maria Matsangou et al. · Journal of Clinical Oncology · 2024 · 15 citations

Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

Kohei Shitara, Eric Van Cutsem, Florian Lordick et al. · Journal of Clinical Oncology · 2024 · 11 citations